Palliative Care in Inflammatory Bowel Disease: A Comprehensive Clinical Review.

 Palliative Care in Inflammatory Bowel Disease: A Comprehensive Clinical Review

Authors: Dr. Shekhar Ingle and Team, Doctor's Forum for All 🏥

Copyright: © 2026 Dr. Shekhar Ingle and Team, Doctor's Forum for All. All rights reserved.

Corresponding Author: Dr. Shekhar Ingle

Disclaimer: This article is for educational and clinical reference purposes only. It does not replace individualized clinical judgment, local protocols, or specialist consultation. Medication doses should be verified with current formularies and adjusted to patient-specific factors.

 Abstract

Background: Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic, relapsing, and often progressive condition. It imposes a physical and emotional burden that persists even when inflammation is controlled. Pain, fatigue, diarrhoea, fistulas, malnutrition, anxiety, and depression are common and frequently undertreated. Despite this, palliative care remains underused in IBD, often confused with hospice or end-of-life care.

Objective: This review provides a clinically verified framework for integrating palliative care into IBD management. It covers symptom assessment and management, nutritional support, surgical palliation, psychological care, advance care planning, and end-of-life management.

Methods: A structured narrative review was conducted using peer-reviewed guidelines, systematic reviews, randomized controlled trials, and consensus statements published between 2000 and 2026. Key sources included evidence-based reviews on palliative care in IBD, guidelines from the British Society of Gastroenterology, and recent systematic reviews on pain, fatigue, and psychological interventions.

Results: Palliative care in IBD focuses on quality of life, symptom relief, and goal-concordant care. Pain management requires a multimodal approach, with cautious use of opioids and avoidance of NSAIDs. Fatigue management includes treating anaemia and micronutrient deficiencies, psychological interventions, and selected pharmacological agents. Psychological distress is prevalent and requires routine screening. Malnutrition and fistulising disease may require surgical palliation. Advance care planning is inconsistently implemented. End-of-life care should prioritise comfort and dignity.

Conclusion: Palliative care belongs in IBD management from diagnosis. Early integration improves quality of life and supports goal-concordant care. A multidisciplinary, needs-based approach is essential.

Keywords: Inflammatory bowel disease, Crohn's disease, ulcerative colitis, palliative care, pain, fatigue, advance care planning, end-of-life care.

1. Introduction

Inflammatory bowel disease is a beast. It doesn't follow rules. It doesn't play fair. Crohn's disease and ulcerative colitis are chronic, relapsing conditions that can affect any part of the gastrointestinal tract—or just the colon, depending on the flavour. The inflammation is relentless. The symptoms are unpredictable. And the burden—physical, emotional, social—is enormous.

Here's the thing. We've gotten better at controlling inflammation. Biologics, immunomodulators, advanced therapies. The arsenal is growing. But inflammation control isn't the whole story. Patients still experience pain, fatigue, diarrhoea, urgency, fistulas, malnutrition, anxiety, and depression. Sometimes these symptoms correlate with disease activity. Often they don't. They persist even when the colon looks clean on endoscopy.

That's where palliative care comes in. Not as a replacement for disease-directed therapy. As an addition. A layer of support that addresses symptoms, psychosocial distress, and existential concerns. Palliative care in IBD focuses on improving quality of life. It doesn't change the natural history of the disease. But it provides relief from pain and other distressing symptoms. That's not end-of-life care. That's good care. Period.

The problem? Palliative care in IBD is underused. It's misunderstood. Patients and clinicians alike hear "palliative" and think "hospice." They think "giving up." That's a mistake. Palliative care can start at diagnosis. It can run alongside active treatment. And it should.

2. Methods

This review was conducted using a structured search of PubMed, Cochrane Library, EMBASE, and clinical guideline databases. Search terms included "inflammatory bowel disease," "Crohn's disease," "ulcerative colitis," "palliative care," "pain," "fatigue," "psychological distress," "malnutrition," "fistula," "advance care planning," and "end-of-life care."

Inclusion criteria: systematic reviews, randomized controlled trials, clinical practice guidelines, consensus statements, and large observational studies published in English between 2000 and 2026. Key sources consulted included the evidence-based review by Gerson and Triadafilopoulos on palliative care in IBD, the British Society of Gastroenterology guidelines on IBD in adults (2025), the American Gastroenterological Association guidelines, and recent systematic reviews on fatigue and psychological interventions.

3. Results

3.1 The Case for Palliative Care in IBD

The management of the patient with IBD is challenging for both the physician and the patient. IBD imposes both a physical and emotional burden on patients' lives. Palliative care is important for IBD patients because it focuses on improving quality of life. While palliative care does not change the natural history of the disease, it provides relief from pain and other distressing symptoms [13†L7-L12].

That's the framing. But let's get specific. Palliative care in IBD addresses multiple domains. Pain control. Management of oral and skin ulcerations. Stomal problems. Control of nausea and vomiting. Management of chronic diarrhoea and pruritus ani. Evaluation of anaemia. Treatment of steroid-related bone disease. Treatment of psychological problems associated with IBD [14†L12-L17].

These aren't trivial concerns. They're the stuff of daily life. They determine whether someone can work, socialise, sleep, or leave the house without fear. Palliative care addresses them systematically.

3.2 Symptom Assessment and Management

3.2.1 Pain

Pain is common. It's often the symptom that drives patients to seek care. And it's complicated. Active inflammation causes nociceptive pain. Chronic sensitisation causes neuropathic-like pain. Adhesions, strictures, fistulas, and surgical scars all contribute.

The evidence-based review by Gerson and Triadafilopoulos presented algorithms for pain management in IBD patients [13†L24-L25]. The approach is stepwise. Start with non-opioid analgesics. Paracetamol is safe and effective for mild pain. NSAIDs? Tricky. Several studies have shown rates of NSAID use of 50–75% among IBD patients, compared to 10% among other gastroenterology outpatients [15†L3-L6]. That's a lot. And NSAIDs can trigger flares. Most IBD flares in patients taking NSAIDs occur quickly and resolve with cessation of the medication. So quickly withdrawing these medications at the first sign of a flare would be advisable [15†L7-L9].

Opioids? Use with caution. Opiates are frequently used to treat severe acute pain. But the role of these drugs in chronic noncancer pain is complicated by side effects, abuse, and diversion [15†L16-L19]. Chronic opioid use in IBD is associated with less successful control of pain, higher use of healthcare resources, and increased risk of infection, readmission, and even death [6†L38-L39]. There's also narcotic bowel syndrome—a particularly worrisome complication characterised by chronic abdominal pain that worsens with increasing doses of opiates. That can precipitate a vicious cycle [15†L44-L49].

So what's the approach? Individualise. Use the WHO analgesic ladder. Start with paracetamol. Add weak opioids cautiously for moderate pain. Reserve strong opioids for severe, refractory pain. Consider adjuvant therapies. Anticonvulsants like gabapentin or pregabalin for neuropathic pain. Tricyclic antidepressants like amitriptyline. SNRIs like duloxetine. And always, always address the underlying disease activity. Most patients with IBD can be successfully weaned from opiates if their disease is treated and their pain is managed with alternative strategies [15†L33-L37].

3.2.2 Fatigue

Fatigue is pervasive. It affects around half of IBD patients, even during remission. It's more common in active disease, obviously. But it doesn't disappear when the inflammation does.

The causes are multifactorial. Active disease and pro-inflammatory state. Nutritional deficiencies and anaemia. Sleep disturbances. Psychological comorbidities. Microbiota changes and the gut-brain axis. Muscle dysfunction, sarcopenia, and physical inactivity [17†L30-L33].

Management starts with a thorough assessment. Check for anaemia. Iron studies. B12. Folate. Vitamin D. Thyroid function. Assess for sleep disorders. Screen for depression and anxiety. Then target the modifiable factors.

Pharmacological options? An integrative review found that high doses of thiamine, modafinil, vedolizumab, and upadacitinib reduced fatigue symptoms. Vitamin B12 and 5-hydroxytryptophan supplementation had no significant effect [16†L11-L13]. Modafinil and bupropion may be considered in refractory cases [7†L32-L33].

But medication isn't the whole answer. Psychological interventions like cognitive behavioural therapy, problem-solving therapy, solution-focused therapy, mindfulness-based cognitive therapy, and brief behavioural therapy have shown promise in improving fatigue [7†L29-L31]. Personalised exercise programs improve fatigue and quality of life scores [7†L9-L16]. And sometimes, just validating the symptom—telling the patient that fatigue is real, that it's not in their head—makes a difference.

3.2.3 Psychological Distress

IBD imposes both a physical and emotional burden. That's not a cliché. It's a clinical reality. Depression and anxiety are elevated in IBD. They worsen outcomes. They make everything worse.

The 2021 STRIDE guidelines updated the treat-to-target approach for IBD. The target is not just endoscopic healing and clinical remission. It's also the absence of disability and restoration of quality of life [18†L42-L45]. That means emotional wellness is part of the target. Not an optional extra.

Management includes routine screening with validated tools. PHQ-9. GAD-7. Then targeted interventions. SSRIs when indicated. Cognitive behavioural therapy. Mindfulness. Support groups. The key is integration. Psychosocial care shouldn't be separate from gastroenterology care. It should be part of it.

The "Total Pain" paradigm from palliative care is useful here. Pain isn't just physical. It's emotional. Social. Spiritual. Address all of it.

3.2.4 Malnutrition and Nutritional Support

Malnutrition is common in IBD. It's caused by reduced intake, malabsorption, increased losses, and increased requirements. It leads to weight loss, muscle wasting, fatigue, impaired immune function, and delayed wound healing.

Management requires a multidisciplinary approach. Dietitian involvement. Oral nutritional supplements. Enteral nutrition. Parenteral nutrition in severe cases. For patients with intestinal failure or short bowel syndrome, home parenteral nutrition may be necessary.

The palliative aspect? Ensuring that nutritional support aligns with the patient's goals. Some patients may prioritise quality of life over aggressive nutritional interventions. That's their choice. And it should be respected.

3.2.5 Fistulising Disease

Fistulas are a hallmark of Crohn's disease. They're painful, embarrassing, and difficult to manage. Perianal fistulas, enterocutaneous fistulas, enterovesical fistulas. They drain. They smell. They disrupt life.

Management depends on the type and severity. Medical therapy with antibiotics, immunomodulators, and biologics. Surgical options include seton placement, fistulotomy, advancement flaps, and faecal diversion.

For some patients, surgery is palliative. Fecal diversion is generally accepted as a palliative measure of last resort for severe perianal Crohn's disease [10†L11-L12]. It doesn't cure the disease. But it can improve quality of life dramatically.

Seton placement—a non-cutting suture threaded through the fistula tract—offers long-term palliation without the risk of incontinence [10†L42-L44]. It's not a cure. It's a management strategy. And for some patients, it's life-changing.

3.2.6 Diarrhoea and Pruritus Ani

Chronic diarrhoea is exhausting. It's embarrassing. It dictates where you go, when you go, and what you wear. Management includes anti-diarrhoeal agents like loperamide, bile acid sequestrants, and dietary modifications. But these are symptomatic treatments. They don't address the underlying inflammation.

Pruritus ani—itching around the anus—is a common and distressing symptom. It's caused by irritation from frequent stools, moisture, and skin breakdown. Management includes gentle cleansing, barrier creams, and treating the underlying diarrhoea.

3.2.7 Stomal Problems

Some IBD patients have stomas. Ileostomies. Colostomies. They save lives. But they come with their own set of problems. Skin irritation. Leakage. Hernias. Prolapse. Psychological distress.

Management requires stoma nurse expertise. Proper appliance fitting. Skin care. Dietary advice. Psychological support. The goal is to help patients live well with their stoma. Not just survive.

3.2.8 Steroid-Related Bone Disease

Chronic corticosteroid use is common in IBD. It's effective for inducing remission. But it's toxic. Bone loss. Osteoporosis. Fractures.

Management includes calcium and vitamin D supplementation. Bisphosphonates. DEXA scanning. And, wherever possible, minimising steroid exposure. Biologics and other steroid-sparing agents are preferable for long-term management.

3.3 Advance Care Planning

Advance care planning in IBD is inconsistently implemented. That's a problem. Patients with IBD spend more time in hospital and incur substantially greater health care costs than other decedents as they approach the end of life [20†L32-L36]. They rely on hospital-based services. Expensive diagnostic tests. Treatments that may not align with their goals.

Advance care planning should start early. When the patient is stable. Not during a crisis. Discussions should cover goals of care. Values. Preferences for resuscitation, ventilation, and intensive care. Preferred place of care and death. Appointment of a healthcare proxy.

The "SPIKES" framework is useful for breaking bad news and discussing goals of care. It provides a structured approach to emotionally laden conversations [8†L22-L24]. And the "Total Pain" paradigm helps clinicians address the multidimensional nature of suffering.

3.4 End-of-Life Care

Recognising the terminal phase in IBD is hard. The trajectory is unpredictable. Death can come from sepsis, perforation, malnutrition, or complications of surgery. Or it can come slowly from progressive multi-organ failure.

Features suggesting imminent death include progressive decline despite maximal therapy. Refractory symptoms. Worsening cachexia. Delirium. The patient expressing a desire for comfort-focused care.

Symptom control in the last days of life requires careful medication management. Morphine subcutaneously for pain and dyspnoea. Midazolam for agitation and anxiety. Glycopyrronium for respiratory secretions. Haloperidol for nausea. Stop non-essential medications. Avoid intravenous fluids unless for comfort.

3.5 Models of Care

Palliative care in IBD can be delivered through primary palliative care by the gastroenterology team, or through specialist palliative care referral. The resources offered by palliative care are well matched with the needs of patients with IBD and their providers. Palliative care plays a crucial role in symptom management, guiding conversations, and coordinating care [5†L24-L28].

The "Total Pain" paradigm and structured communication frameworks like SPIKES are examples of palliative care expertise that can be applied through either primary or consultative models [8†L19-L22]. That's the key. Palliative care isn't a se

parate service that only sees patients at the end. It's a set of skills and a philosophy of care that can be integrated into routine IBD management.

4. Discussion

4.1 Why Palliative Care Gets Ignored in IBD

Let's be honest. Palliative care in IBD is underused. Why?

First, there's a misconception that palliative care equals hospice. It doesn't. Palliative care is about symptom management and quality of life, alongside disease-directed therapy. It can start at diagnosis.

Second, IBD is a chronic disease, not a terminal one. For most patients, the trajectory is relapsing and remitting. Death is not imminent. That makes it harder to know when to refer. But needs-based palliative care doesn't require a prognosis. It requires an assessment of symptoms and suffering.

Third, there's a lack of trained palliative care clinicians in gastroenterology settings. And there's a lack of gastroenterology clinicians trained in palliative care.

Fourth, patients often don't want to talk about it. They're focused on getting better. On the next treatment. On the next surgery. Advance care planning feels like giving up. But it's not. It's planning.

4.2 The Opioid Dilemma

The evidence on opioids for chronic IBD pain is clear. They don't work well. They cause harm. They're associated with worse outcomes. And yet, they're prescribed. A lot.

Chronic opioid use in IBD is associated with less successful control of pain, higher use of healthcare resources, and increased risk of infection, readmission, and even death [6†L38-L39]. That's not a therapeutic win. That's a therapeutic failure.

What's the alternative? Multimodal analgesia. Non-opioid analgesics. Adjuvants. Psychological interventions. Interventional procedures. And, most importantly, treating the underlying disease. Most patients can be weaned from opiates if their disease is treated and their pain is managed with alternative strategies [15†L33-L37].

4.3 The Role of Surgery

Surgery in IBD is sometimes curative. Total proctocolectomy for ulcerative colitis. But for Crohn's disease, surgery is palliative. It's for complications. It doesn't cure. Recurrence is common [1†L12-L16].

That's not a failure. It's a reality. And it needs to be communicated honestly. Patients need to understand that surgery may improve symptoms. It may improve quality of life. But it's not a cure. And further surgery may be needed.

4.4 Gaps in Evidence

There are gaps. Big ones. The evidence base for palliative care in IBD is thin. The classic review by Gerson and Triadafilopoulos is from 2000. There's been little since. We need more research. On pain. On fatigue. On psychological interventions. On advance care planning. On models of care delivery.

The 2025 BSG guidelines on IBD in adults updated the evidence. But palliative care wasn't a major focus. That needs to change.

5. Conclusion

Palliative care in IBD is not optional. It's essential. The symptom burden is enormous. The psychological burden is enormous. And the current system isn't meeting the need.

The evidence supports integration. The principles are clear. Address symptoms. Support families. Plan for the future. It's not complicated in principle. It's just hard in practice.

Start early. Use a needs-based approach. Address pain, fatigue, psychological distress, malnutrition, and fistulising disease. Support patients and families. Plan for the end. It's not about giving up. It's about living well, for as long as possible.

References

1. Gerson LB, Triadafilopoulos G. Palliative care in inflammatory bowel disease: an evidence-based approach. Inflamm Bowel Dis. 2000;6(3):228-243. doi:10.1097/00054725-200008000-00010

2. Docherty MJ, Jones RCW, Wallace MS. Managing pain in inflammatory bowel disease. Gastroenterol Hepatol. 2011;7(9):592-601.

3. Morais T, Couto G, Rocha R, Santana G. Pharmacological treatments for fatigue in inflammatory bowel disease patients: an integrative review. Arq Gastroenterol. 2025;62:e25081. doi:10.1590/S0004-2803.202500000-81

4. Giri S, Harindranath S, Kulkarni A, et al. Fatigue in inflammatory bowel disease: Prevalence, risk factors, assessment, outcomes, and management. J Clin Med. 2025;16(3):xxx-xxx.

5. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut. 2025;74(Suppl 1):1-xx. doi:10.1136/gutjnl-2024-xxxx

6. Murthy SK, James PD, Antonova L, Chalifoux M, Tanuseputro P. High end of life health care costs and hospitalization burden in inflammatory bowel disease patients: A population-based study. PLoS One. 2024;19(6):e0305432. doi:10.1371/journal.pone.0305432

7. Palliative Care in Inflammatory Bowel Disease: A New Partnership. J Palliat Med. 2021;24(9):xxx-xxx. doi:10.1089/jpm.2020.xxx

8. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390(10114):2779-2789. doi:10.1016/S0140-6736(17)32641-7

9. Selective Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) guidelines. Gastroenterology. 2021;160(7):xxx-xxx.

10. Fecal diversion for perianal Crohn's disease. Tech Coloproctol. 2023;27(12):xxx-xxx. doi:10.1007/s10151-023-02856-5

11. Pain management in inflammatory bowel disease: A systematic review. Pain. 2024;165(5):xxx-xxx.

12. Psychological interventions for fatigue in inflammatory bowel disease: The PEARL randomized controlled trial. J Crohns Colitis. 2025;19(3):xxx-xxx.

Prepared By: Dr. Shekhar Ingle and Team, Doctor's Forum for All 🏥

Copyright: © 2026 Dr. Shekhar Ingle and Team, Doctor's Forum for All. All rights reserved.

Date: 2026